← Oncology Approval Tracker

FDA DECISION ·

Zenbexus + Darzalex Faspro + dexamethasone

iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone · Bristol Myers Squibb

Accelerated approvalNew therapyMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with multiple myeloma who have had at least one prior line that included both a proteasome inhibitor and an immunomodulatory drug.

LAMPGEN ANALYSIS

Why it matters

This adds an iberdomide-based regimen after prior treatment. Keep the endpoint underlying accelerated approval separate from the evidence expected to verify clinical benefit.

What research teams should watch

Capture prior drug-class exposure and resistance in a structured history. The confirmatory program will depend on consistent marrow assessment and follow-up.

PRIMARY RECORDS

Sources